Abaloparatide

Abaloparatide is an FDA-approved subcutaneous bone-anabolic peptide for high-risk osteoporosis. It reduced vertebral fractures in studied postmenopausal women; it is not an adult-height intervention.

tier S · healing · 0.6% vs 4.2% new vertebral fractures in ACTIVE

verdict

Daily subcutaneous abaloparatide reduced new vertebral fractures in postmenopausal women with osteoporosis and increased BMD in men with osteoporosis. Neither trial measured adult height or reopening of growth plates.

the core tension

Abaloparatide has strong osteoporosis evidence and a clear bone-anabolic mechanism. Calling that adult height confuses remodeling of existing bone with longitudinal growth at an open plate.

what it is

Abaloparatide is a synthetic 34-amino-acid analog of PTHrP(1-34) and an agonist at the PTH1 receptor.

what it does

PTH1-receptor activation stimulates osteoblastic bone formation on trabecular and cortical surfaces. That is bone remodeling and strengthening, not restoration of an ossified growth plate.

origin

TYMLOS was first approved in the United States in 2017. The reviewed label covers a subcutaneous prefilled-pen product for specified high-fracture-risk osteoporosis populations.

does it work

Yes, for the labeled osteoporosis outcomes. ACTIVE showed fewer new vertebral fractures in postmenopausal women, and ATOM showed larger BMD gains in men. It does not provide an adult-height result.

key facts

• molecular formula: C174H300N56O49
• molecular weight: 3961 g/mol
• amino acids: 34 amino acids
• half-life: about 1 h after the specified subcutaneous TYMLOS formulation
• type: synthetic PTHrP(1-34) analog and PTH1-receptor agonist
• CAS: 247062-33-5
• 2,463 postmenopausal women randomized in ACTIVE
• 228 men randomized in ATOM
• 0 adult-height endpoints in the cited pivotal trial registry

frequently asked questions

Can abaloparatide make an adult taller?

No. It is not an adult-height intervention. Once mature growth plates have closed and been replaced by bone, abaloparatide does not reopen them.

What does it actually treat?

The reviewed FDA label covers specified women and men with osteoporosis at high fracture risk.

Does it reduce fractures?

In ACTIVE, postmenopausal women with osteoporosis had fewer new vertebral fractures with abaloparatide than placebo over 18 months.

Why are open epiphyses mentioned in the warning?

The label avoids use in patients with open epiphyses because they have increased baseline osteosarcoma risk. That warning is not evidence that the drug lengthens bones.

What is its half-life?

The label reports about 1 hour after the specified subcutaneous TYMLOS formulation, with a median Tmax of 0.51 hours.

related peptides

• bpc-157: compare against the population-specific fracture and BMD record here

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.